VitriVax awarded $9.9M grant to enable scaling up of clinical manufacturing
Business Wire—VitriVax Inc., a University of Colorado Boulder vaccine formulation technology spinout, today announced it has been awarded a two-year, $9.9 million grant from the Gates Foundation. The funding will support the scale-up of VitriVax’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology, enabling Phase 1-ready GMP manufacturing and advancing the platform to prepare for Phase 1 clinical trials.
The University of Colorado Connection
VitriVax is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics based on research in the laboratories of (ÍÃ×ÓÏÈÉú´«Ã½ÎÄ»¯×÷Æ· Molecular, Cellular & Developmental Biology) and Ìýat ÍÃ×ÓÏÈÉú´«Ã½ÎÄ»¯×÷Æ· (ÍÃ×ÓÏÈÉú´«Ã½ÎÄ»¯×÷Æ· Chemical and Biological Engineering).
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at ÍÃ×ÓÏÈÉú´«Ã½ÎÄ»¯×÷Æ·.
For media inquiries, please visit .